Trials / Terminated
TerminatedNCT00889421
Apremilast in the Treatment of Uveitis
An Open-label Trial to Assess the Efficacy and Safety of Apremilast in the Management of Vision-threatening Uveitis That is Refractory to Other Modes of Systemic Immunosuppression.
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 3 (actual)
- Sponsor
- Oregon Health and Science University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and efficacy of Apremilast in the treatment of uveitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apremilast | oral dose of 30 mg BID for 6 months |
Timeline
- Start date
- 2009-11-01
- Primary completion
- 2011-06-01
- Completion
- 2011-06-01
- First posted
- 2009-04-28
- Last updated
- 2014-07-08
- Results posted
- 2014-07-08
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00889421. Inclusion in this directory is not an endorsement.